Skip to main content
Erschienen in: Investigational New Drugs 2/2008

01.04.2008 | Preclinical Studies

Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis

verfasst von: Fran Supek, Marijeta Kralj, Marko Marjanović, Lidija Šuman, Tomislav Šmuc, Irena Krizmanić, Biserka Žinić

Erschienen in: Investigational New Drugs | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Summary

We have previously shown that N-1-sulfonylpyrimidine derivatives have strong antiproliferative activity on human tumor cell lines, whereby 1-(p-toluenesulfonyl)cytosine showed good selectivity with regard to normal cells and was easily synthesized on a large scale. In the present work we have used an interdisciplinary approach to elucidate the compounds’ mechanistic class. An augmented number of cell lines (11) has allowed a computational search for compounds with similar activity profiles and/or mechanistic class by integrating our data with the comprehensive DTP–NCI database. We applied supervised machine learning methodology (Random Forest classifier), which offers information complementary to unsupervised algorithms commonly used for analysis of cytostatic activity profiles, such as self-organizing maps. The computational results taken together with cell cycle perturbation and apoptosis analysis of the cell lines point to an unusual mechanism of cytostatic action, possibly a combination of nucleic acid antimetabolite activity and a novel molecular mechanism.
Literatur
1.
Zurück zum Zitat Erhardt PW (2002) Medicinal chemistry in the new millennium. A glance into the future. Pure Appl Chem 74:703–785CrossRef Erhardt PW (2002) Medicinal chemistry in the new millennium. A glance into the future. Pure Appl Chem 74:703–785CrossRef
2.
Zurück zum Zitat Oprea TI, Gottfries J (2001) Chemography: the art of navigating in chemical space. J Com Chem 3:157–166CrossRef Oprea TI, Gottfries J (2001) Chemography: the art of navigating in chemical space. J Com Chem 3:157–166CrossRef
3.
Zurück zum Zitat MacCoss M, Robins MJ (1990) In: Wilman DEV (ed) Chemistry of antitumor agents. Blackie and Son, Glasgow, Scotland, p 261 MacCoss M, Robins MJ (1990) In: Wilman DEV (ed) Chemistry of antitumor agents. Blackie and Son, Glasgow, Scotland, p 261
4.
Zurück zum Zitat Robins RK, Kirin GD (1990) In: Wilman DEV (ed) Chemistry of antitumor agents. Blackie and Son, Glasgow, Scotland, p 299 Robins RK, Kirin GD (1990) In: Wilman DEV (ed) Chemistry of antitumor agents. Blackie and Son, Glasgow, Scotland, p 299
5.
Zurück zum Zitat Robins RK, Revankar GR (1988) In: De Clercq E, Walker RT (eds) Antiviral drug development. Plenum, New York, p 11 Robins RK, Revankar GR (1988) In: De Clercq E, Walker RT (eds) Antiviral drug development. Plenum, New York, p 11
6.
Zurück zum Zitat Kašnar B, Krizmanić I, Žinić M (1997) Synthesis of the sulfonylpirimidine derivatives as a new type of sulfonylcycloureas. Nucleosides Nucleotides 16:1067–1071CrossRef Kašnar B, Krizmanić I, Žinić M (1997) Synthesis of the sulfonylpirimidine derivatives as a new type of sulfonylcycloureas. Nucleosides Nucleotides 16:1067–1071CrossRef
7.
Zurück zum Zitat Žinić B, Krizmanić I, Vikić-Topić D, Žinić M (1999) 5-Bromo- and 5-iodo-N-1-sulfonylated cytosine derivatives. Exclusive formation of keto-imino tautomers. Croat Chem Acta 72:957–966 Žinić B, Krizmanić I, Vikić-Topić D, Žinić M (1999) 5-Bromo- and 5-iodo-N-1-sulfonylated cytosine derivatives. Exclusive formation of keto-imino tautomers. Croat Chem Acta 72:957–966
8.
Zurück zum Zitat Žinić B, Žinić M, Krizmanić I (2003) Synthesis of the sulfonylpyrimidine derivatives with anticancer activity. EP 0 877 022 B1 Žinić B, Žinić M, Krizmanić I (2003) Synthesis of the sulfonylpyrimidine derivatives with anticancer activity. EP 0 877 022 B1
9.
Zurück zum Zitat Slišković DR, Krause BR, Bocan TMA (1999) In: Doherty AM, Greenlee W, Hagmann WK (eds) Annual Reports in Medicinal Chemistry 34:101–110 Slišković DR, Krause BR, Bocan TMA (1999) In: Doherty AM, Greenlee W, Hagmann WK (eds) Annual Reports in Medicinal Chemistry 34:101–110
10.
Zurück zum Zitat Melander A (1996) Oral antidiabetic drugs: an overview. Diabet Med 13:S143–S147PubMed Melander A (1996) Oral antidiabetic drugs: an overview. Diabet Med 13:S143–S147PubMed
11.
Zurück zum Zitat Furlong ET, Burkhardt MR, Gates PM, Werner SL, Battaglin WA (2000) Routine determination of sulfonylurea, imidazolinone, and sulfonamide herbicides at nanogram-per-liter concentrations by solid-phase extraction and liquid chromatography/mass spectrometry. Sci Total Environ 248:135–146PubMedCrossRef Furlong ET, Burkhardt MR, Gates PM, Werner SL, Battaglin WA (2000) Routine determination of sulfonylurea, imidazolinone, and sulfonamide herbicides at nanogram-per-liter concentrations by solid-phase extraction and liquid chromatography/mass spectrometry. Sci Total Environ 248:135–146PubMedCrossRef
12.
Zurück zum Zitat Houghton PJ, Sosinski J, Thakar JH, Boder GB, Grindey GB (1995) Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N′-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol 49:661–668PubMedCrossRef Houghton PJ, Sosinski J, Thakar JH, Boder GB, Grindey GB (1995) Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N′-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol 49:661–668PubMedCrossRef
13.
Zurück zum Zitat Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB (1993) Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5:223–228PubMed Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB (1993) Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5:223–228PubMed
14.
Zurück zum Zitat Mohamadi F, Spees MM, Grindey GB (1992) Sulfonylureas: a new class of cancer chemotherapeutic agents. J Med Chem 35:3012–3016PubMedCrossRef Mohamadi F, Spees MM, Grindey GB (1992) Sulfonylureas: a new class of cancer chemotherapeutic agents. J Med Chem 35:3012–3016PubMedCrossRef
15.
Zurück zum Zitat Morre DJ, Wu LY, Morre DM (1998) Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenylurea) (LY181984) modulated by redox. Biochim Biophys Acta 1369:185–192PubMedCrossRef Morre DJ, Wu LY, Morre DM (1998) Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenylurea) (LY181984) modulated by redox. Biochim Biophys Acta 1369:185–192PubMedCrossRef
16.
Zurück zum Zitat Toth JE, Grindey GB, Ehlhardt WJ, Ray JE, Boder GB, Bewley JR, Klingerman KK, Gates SB, Rinzel SM, Schultz RM, Weir LC, Worzalla JF (1997) Sulfonimidamide analogs of oncolytic sulfonylureas. J Med Chem 40:1018–1025PubMedCrossRef Toth JE, Grindey GB, Ehlhardt WJ, Ray JE, Boder GB, Bewley JR, Klingerman KK, Gates SB, Rinzel SM, Schultz RM, Weir LC, Worzalla JF (1997) Sulfonimidamide analogs of oncolytic sulfonylureas. J Med Chem 40:1018–1025PubMedCrossRef
17.
Zurück zum Zitat Glavaš-Obrovac L, Karner I, Žinić B, Pavelić K (2001) Antineoplastic activity of novel N-1-sulfonypyrimidine derivatives. Anticancer Res 21:1979–1986PubMed Glavaš-Obrovac L, Karner I, Žinić B, Pavelić K (2001) Antineoplastic activity of novel N-1-sulfonypyrimidine derivatives. Anticancer Res 21:1979–1986PubMed
18.
Zurück zum Zitat Glavaš-Obrovac L, Karner I, Štefanić M, Kašnar-Šamprec J, Žinić B (2005) Metabolic effects of novel N-1-sulfonylpyrimidine derivatives on human colon carcinoma cells. Farmaco 60:479–483PubMedCrossRef Glavaš-Obrovac L, Karner I, Štefanić M, Kašnar-Šamprec J, Žinić B (2005) Metabolic effects of novel N-1-sulfonylpyrimidine derivatives on human colon carcinoma cells. Farmaco 60:479–483PubMedCrossRef
19.
Zurück zum Zitat Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91–109CrossRef Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91–109CrossRef
20.
Zurück zum Zitat Martirosyan A, Gunar VI, Zav’yalov SI (1970) Tosylation of nitrogenous components of nucleic acids. Akad Nauk SSSR, Ser Khim 8:1841–1844 Martirosyan A, Gunar VI, Zav’yalov SI (1970) Tosylation of nitrogenous components of nucleic acids. Akad Nauk SSSR, Ser Khim 8:1841–1844
21.
Zurück zum Zitat Kaldrikyn MA, Geboyan VA, Ter-Yakharyn YZ, Paronikyan RV, Garibdzhanyan BT, Stepanyan GM, Paronikyan GM (1986) Synthesis and biological activity of N′-4-alkoxybenzenesulfonyl-5-halouracils. Khim Farm Zh 20:928–932 Kaldrikyn MA, Geboyan VA, Ter-Yakharyn YZ, Paronikyan RV, Garibdzhanyan BT, Stepanyan GM, Paronikyan GM (1986) Synthesis and biological activity of N′-4-alkoxybenzenesulfonyl-5-halouracils. Khim Farm Zh 20:928–932
22.
Zurück zum Zitat Tada M (1975) Antineoplastic agents. Synthesis of some 1-substituted 5-fluorouracil derivatives. Chem Lett 4:129–130CrossRef Tada M (1975) Antineoplastic agents. Synthesis of some 1-substituted 5-fluorouracil derivatives. Chem Lett 4:129–130CrossRef
23.
Zurück zum Zitat Kašnar-Šamprec J, Glavaš-Obrovac L, Pavlak M, Mihaljević I, Mrljak V, Štambuk N, Konjevoda P, Žinić B (2005) Synthesis, spectroscopic characterization and biological activity of N-1-sulfonylcytosine derivatives. Croat Chem Acta 78:261–267 Kašnar-Šamprec J, Glavaš-Obrovac L, Pavlak M, Mihaljević I, Mrljak V, Štambuk N, Konjevoda P, Žinić B (2005) Synthesis, spectroscopic characterization and biological activity of N-1-sulfonylcytosine derivatives. Croat Chem Acta 78:261–267
25.
27.
Zurück zum Zitat Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116–5121PubMedCrossRef Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116–5121PubMedCrossRef
28.
Zurück zum Zitat Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and Compare algorithm. J Natl Cancer Inst 81:1088–1092PubMedCrossRef Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and Compare algorithm. J Natl Cancer Inst 81:1088–1092PubMedCrossRef
29.
Zurück zum Zitat Rabow AA, Shoemaker RH, Sausville EA, Covell DG (2002) Mining the National Cancer Institute’s tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 45:818–840PubMedCrossRef Rabow AA, Shoemaker RH, Sausville EA, Covell DG (2002) Mining the National Cancer Institute’s tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 45:818–840PubMedCrossRef
30.
Zurück zum Zitat Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6:65–70 Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6:65–70
31.
Zurück zum Zitat Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF (2000) Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60:5196–5203PubMed Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF (2000) Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60:5196–5203PubMed
32.
Zurück zum Zitat Monks A, Harris E, Hose C, Connelly J, Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766–772PubMedCrossRef Monks A, Harris E, Hose C, Connelly J, Sausville EA (2003) Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63:766–772PubMedCrossRef
33.
Zurück zum Zitat Qi Y, Bar-Joseph Z, Klein-Seetharaman J (2006) Evaluation of different biological data and computational classification methods for use in protein interaction prediction. Proteins 63:490–500PubMedCrossRef Qi Y, Bar-Joseph Z, Klein-Seetharaman J (2006) Evaluation of different biological data and computational classification methods for use in protein interaction prediction. Proteins 63:490–500PubMedCrossRef
35.
Zurück zum Zitat Capranico G, Binaschi M (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta 1400:185–194PubMed Capranico G, Binaschi M (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta 1400:185–194PubMed
36.
Zurück zum Zitat Grem JL (2000) 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299–313PubMedCrossRef Grem JL (2000) 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299–313PubMedCrossRef
37.
Zurück zum Zitat Koch-Paiz CA, Amundson SA, Bittner ML, Meltzer PS, Fornace AJ, Jr (2004) Functional genomics of UV radiation responses in human cells. Mutat Res 549:65–78PubMed Koch-Paiz CA, Amundson SA, Bittner ML, Meltzer PS, Fornace AJ, Jr (2004) Functional genomics of UV radiation responses in human cells. Mutat Res 549:65–78PubMed
38.
Zurück zum Zitat Marchal JA, Boulaiz H, Suarez I, Saniger E, Campos J, Carrillo E, Prados J, Gallo MA, Espinosa A, Aranega A (2004) Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Invest New Drugs 22:379–389PubMedCrossRef Marchal JA, Boulaiz H, Suarez I, Saniger E, Campos J, Carrillo E, Prados J, Gallo MA, Espinosa A, Aranega A (2004) Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Invest New Drugs 22:379–389PubMedCrossRef
39.
Zurück zum Zitat Marjanović M, Kralj M, Supek F, Frkanec L, Piantanida I, Šmuc T, Tušek-Božić L (2007) Antitumor potential of crown ethers: structure–activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. J Med Chem 50:1007–1018PubMedCrossRef Marjanović M, Kralj M, Supek F, Frkanec L, Piantanida I, Šmuc T, Tušek-Božić L (2007) Antitumor potential of crown ethers: structure–activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. J Med Chem 50:1007–1018PubMedCrossRef
40.
Zurück zum Zitat Witten IH, Frank E (2005) Data mining: practical machine learning tools and techniques. Morgan Kaufmann, San Francisco Witten IH, Frank E (2005) Data mining: practical machine learning tools and techniques. Morgan Kaufmann, San Francisco
41.
Zurück zum Zitat Covell DG, Wallqvist A, Huang R, Thanki N, Rabow AA, Lu XJ (2005) Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 59:403–433PubMedCrossRef Covell DG, Wallqvist A, Huang R, Thanki N, Rabow AA, Lu XJ (2005) Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 59:403–433PubMedCrossRef
42.
Zurück zum Zitat Breiman L, Friedman J, Stone CJ, Olshen RA (1984) Classification and regression trees. Chapman & Hall, New York Breiman L, Friedman J, Stone CJ, Olshen RA (1984) Classification and regression trees. Chapman & Hall, New York
43.
Zurück zum Zitat Quinlan JR (2006) C4.5: programs for machine learning. Morgan Kaufmann, San Francisco Quinlan JR (2006) C4.5: programs for machine learning. Morgan Kaufmann, San Francisco
Metadaten
Titel
Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis
verfasst von
Fran Supek
Marijeta Kralj
Marko Marjanović
Lidija Šuman
Tomislav Šmuc
Irena Krizmanić
Biserka Žinić
Publikationsdatum
01.04.2008
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 2/2008
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-007-9084-1

Weitere Artikel der Ausgabe 2/2008

Investigational New Drugs 2/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.